γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorChangzhou No.2 People's Hospital
About this trial
This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment of advanced solid tumors.
Eligibility criteria
Qualifiers
The patient voluntarily signs the informed consent and can complete the follow-up examination, evaluation and treatment;
Age 18-80 years old, gender is not limited;
The histopathological diagnosis was malignant solid tumor;
Clinical or pathological was stage IV according to AJCC 8th edition stage;
Disqualifiers
Intolerance or allergy to any ingredient or similar drug in the treatment plan planned for this study;
Metastasis of symptomatic central system;
Have received other cell therapies, including NK, CIK, DC, CTL, CAR-T, TCR-T, and stem cell therapy in the past 4 weeks;
Received systemic steroid therapy (> 10 mg/kg prednisone or equivalent) or any other form of immunosuppressive medication within two weeks prior to the first dose; Corticosteroids (≤10mg oral prednisone or equivalent) were used in subjects with chronic obstructive pulmonary disease, saline corticosteroids (such as hydrohydrocortisone) were used in subjects with postural hypotension, and low-dose supplemental corticosteroids were used in subjects with adrenal insufficiency.
Trial design
Treatments tested in this trial
- γδ T-PD-1 Ab cells
Treatment groups
9 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov